{"entity":{"id":"nct00199043","kind":"trial","name":"Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma","aka":[],"tldr":"A phase 3 trial of Rasburicase in Leukaemia, run by Goethe University, completed.","summary":"Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma is a phase 3 interventional study registered as NCT00199043 by Goethe University, with 80 participants recorded, started 2003-05 and reaching its primary completion in 2008-05. Interventions recorded: Allopurinol, Rasburicase. Conditions recorded: Adult Acute Lymphocytic Leukemia, High-grade Lymphoma.\n\nLinked to the drug Rasburicase because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT00199043","url":"https://clinicaltrials.gov/study/NCT00199043"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["leukaemia"],"sections":[],"technologies":[],"targets":[],"drugs":["rasburicase"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00199043","phase":"3","setting":"Randomised Phase III Trial of Effectivity and Safety of Rasburicase Compared With Allopurinol for Treatment of Hyperuricemia in Patients With Acute Lymphoblastic Leukemia or High-Grade NHL With High Risk of Tumorlysis Syndrome (> 15 Yrs)","sponsor":"Goethe University","enrolled":80,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct00199043/","neighbours":{"cancer":[{"id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/"}],"drug":[{"id":"rasburicase","kind":"drug","name":"Rasburicase","route":"/drugs/rasburicase/"}]}}